Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Litigation
FTC threat ends pact between Maze and Sanofi
by Michael McCoy
December 17, 2023
| A version of this story appeared in
Volume 101, Issue 41
Sanofi has dropped a proposed drug licensing agreement with Maze Therapeutics following a US Federal Trade Commission decision to try to block the pact. The FTC says the deal for Maze’s MZE001, in development to treat Pompe disease, would have eliminated a nascent competitor to Sanofi’s Pompe therapies. In a press release, Maze CEO Jason Coloma says Maze entered the deal with Sanofi because “we believed, and continue to believe, that Sanofi has the optimal resources, expertise, and motivation to advance the program.”
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter